Compare AU

Compare CURE vs. BBUS

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Us Eqy Strong Bear - Ch (Hedge Fund) (BBUS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

BBUS

Popularity

Low

Low

Pearlers invested

80

15

Median incremental investment

$620.00

$5,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,298.77

$1,242.00

Average age group

> 35

> 35


Key Summary

CURE

BBUS

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

BBUS.AX was created on 2015-08-24 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to help investors profit from, or protect against, a declining U.S. share market. It seeks to generate magnified returns that are negatively correlated to the returns of the U.S. share market (as measured by the S&P 500 index), hedged to Australian dollars.

Top 3 holdings

AbbVie Inc (2.62 %)

Alnylam Pharmaceuticals Inc (2.59 %)

Amgen Inc (2.59 %)

S&P500 EMINI FUT MAR25 (0 %)

AUD - AUSTRALIA DOLLAR (101.82 %)

USD - UNITED STATES DOLLAR (-1.82 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Other (73.66 %)

Communication Services (26.34 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

1.38 %


Key Summary

CURE

BBUS

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

1.38 %

Price

$49.20

$4.14

Size

$34.191 million

$142.018 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

1.89 %

Market

ASX

ASX

First listed date

12/11/2018

26/08/2015

Purchase fee

$6.50

$6.50


Community Stats

CURE

BBUS

Popularity

Low

Low

Pearlers invested

80

15

Median incremental investment

$620.00

$5,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,298.77

$1,242.00

Average age group

> 35

> 35


Pros and Cons

CURE

BBUS

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

CURE

BBUS

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Higher distribution yield

Lower distribution yield

Home